Center for Drug Evaluation and Research

Now, when a patient speaks, pharma and the FDA actually listen

By James E. Valentine* - Whether you call it “patient advocacy,” “patient engagement,” or maybe something a little fancier, in recent years incorporating the patient perspective has become a hot topic issue for FDA and drug developers alike. As FDA...